Skip to Main Content
Table 1

Correlation of PSMAa expression status with clinical parameters and disease outcome in 136 cases of prostate cancer treated by radical prostatectomy

Clinical parameter/disease outcomePSMA expression status (no. of patients)Significance (P)
Nonoverexpressingb (71)Overexpressingc (65)
Mean preoperative PSA (ng/ml) 9.10 ± 5.91 18.28 ± 17.70 0.006 
Mean tumor Gleason score 5.92 ± 1.20 6.33 ± 1.21 0.04 
Mean DNA index (diploid = 1.00) 1.03 ± 0.33 1.32 ± 0.50 0.002 
Advanced tumor stage (III/IV) 23/71 (32%) 33/65 (51%) 0.029 
Recurrent disease 20/71 (28%) 37/65 (57%) 0.001 
Mean time to recurrence (mo) 43.75 34.78 0.001 
Clinical parameter/disease outcomePSMA expression status (no. of patients)Significance (P)
Nonoverexpressingb (71)Overexpressingc (65)
Mean preoperative PSA (ng/ml) 9.10 ± 5.91 18.28 ± 17.70 0.006 
Mean tumor Gleason score 5.92 ± 1.20 6.33 ± 1.21 0.04 
Mean DNA index (diploid = 1.00) 1.03 ± 0.33 1.32 ± 0.50 0.002 
Advanced tumor stage (III/IV) 23/71 (32%) 33/65 (51%) 0.029 
Recurrent disease 20/71 (28%) 37/65 (57%) 0.001 
Mean time to recurrence (mo) 43.75 34.78 0.001 
a

PSMA, prostate-specific membrane antigen; PSA, prostate-specific antigen.

b

Low staining intensity.

c

High staining intensity.

Close Modal

or Create an Account

Close Modal
Close Modal